CClinicalTrials.gg
Status unknownNCT02033681Updated Jan 13, 2014

Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution

An interventional study of "One-per-mil" Tumescent Solution Injection and Saline Solution in Ischemia, sponsored by Indonesia University. Status unknown at 1 site in Indonesia. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-13.

Sponsored by Indonesia University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2014), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Male
01

Study summary

The aim of this study is to know the characteristic of "one-per-mil" tumescent solution in regards of the optimal time delay to achieve optimal visualization of operation field in hand and digit surgery.

Hypothesis:

  1. Epinephine in "one-per-mil" concentration by tumescent injection technique will provide faster decrease in oxygen saturation compared to normal saline solution injected by tumescent technique.
  2. Epinephrine in "one-per-mil" concentration by tumescent injection technique will provide effectiveness in vasoconstriction longer than 10 minutes as the optimal time delay.
  3. Epinephine in "one-per-mil" concentration by tumescent injection technique causes no finger necrosis as normal saline solution injected by tumescent technique.
Read the detailed description

This is a prospective, randomized, double-blind study to measure the optimal time delay of 1:1,000,000 epinephrine in saline solution injected by tumescent technique until maximum vasocontriction in the distal finger is achieved.

Subjects will be injected in both his ring fingers(distal phalanges, volar side) with randomized solutions, one containing "one-per-mil" tumescent solution and the other containing only normal saline solution; information which both the injector and examiner are blinded from. Maximum vasoconstriction of the finger injected is depicted by the lowest oxygen saturation (recorded every minute until 45 minutes using pulse oxymeter).

02

Conditions studied

  • Ischemia

Browse trials for

Keywords

  • epinephrine
  • hand
  • ischemia
  • lidocaine
  • upper extremity
03

In context

Ischemia

2,058 studies on the registry are indexed under Ischemia; 347 are open to participants now.

This study's planned enrollment of 12 is below the median of 80 across 1,359 interventional studies indexed under Ischemia.

Browse Ischemia studies →

Lead sponsor

Indonesia University is the lead sponsor of 448 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Willing to join the research
  • BMI 18.5-23
  • Healthy individual, no history of blood or coagulation disorders

Exclusion criteria

Exclusion Criteria:

  • BMI \<18.5 or >23
  • History of blood or coagulation disorder, diabetes mellitus, heavy smoker
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    "One-per-mil" Tumescent Solution

    Procedure: "One-per-mil" Tumescent Solution Injection

  • Placebo comparator
    Saline Solution

    Procedure: Saline Solution

Interventions

  • Procedure"One-per-mil" Tumescent Solution Injection

    "One-per-mil" tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger.

  • ProcedureSaline Solution

    Saline solution is injected into the tissue as a placebo control.

06

What researchers measure

Primary outcomes

  1. Time to achieve lowest oxygen saturation

    After being injected with the solution, the ring finger is put on a continuous monitoring of pulse oxymeter, while the examiner records the decrease of oxygen saturation every minute until 45 minutes length of time. The time when lowest oxygen saturation is achieved is recorded, depicting the optimal time delay to achieve maximum vasoconstriction of the finger after injection.

    Time frame: 45 minutes

Secondary outcomes

  1. Pain Sensation

    Pain sensation of the finger's pulp was examined (using VAS) and recorded every 15 minutes. These data will be compared to the baseline data prior to injection.

    Time frame: 45 minutes

  2. Tactile Sensation

    Tactile sensation of the finger's pulp was examined (using Semmes Weinstein Touch Test) and recorded every 15 minutes after the injection. We will compare this data with the baseline data collected prior to injection.

    Time frame: 45 minutes

  3. Complication

    Subjects will be observed for 6 hours after the injection to record any sign and symptoms related to the complication of the procedure (persisted pain, pallor, numbness).

    Time frame: 6 hours

  4. Decrease in fingertip's temperature

    After injection, temperature of fingertip is measured and recorded every 15 minutes for total time of 45 minutes. The data will be compared with baseline temperature recorded before injection

    Time frame: 45 minutes

07

Study locations

1 site
  • Cipto Mangunkusumo Hospital
    Jakarta, DKI Jakarta 10430, Indonesia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02033681
Lead sponsor
Indonesia University
Responsible party
Theddeus O. H. Prasetyono (Research Coordinator of Plastic Surgery Division, Faculty of Medicine, University of Indonesia, Indonesia University) — Principal investigator
First posted
Jan 13, 2014
Start date
Sep 2013
Primary completion
Jan 2014 (estimated)
Completion
Jan 2014 (estimated)
Last update
Jan 13, 2014

Study contacts

Theddeus OH Prasetyono, MD
principal investigator · Plastic Surgery Division, Faculty of Medicine University of Indonesia/Cipto Mangunkusumo Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion